表紙
市場調查報告書
商品編碼
1017675

Caspase7 - 開發中藥物:2021年

Caspase 7 - Drugs In Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 56 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

Caspase7是一種由 CASP7 基因編碼的人類蛋白質。它參與參與細胞凋亡執行的半胱天冬酶激活級聯反應。甾醇調節元件 分裂並激活結合蛋白。

caspase 7 管道目標由大約 5 個分子組成。其中,約4個分子由企業開發,其餘由大學/機構開發。

本報告提供Caspase7作為對象的治療藥調查分析,提供各適應症,各開發階段,各作用機制,各給藥途徑,各分子類型,各企業,大學/機關別分析為基礎之全面性資訊。

目錄

目錄

  • 簡介
  • 報告的範圍
  • Caspase7 - 概要
  • Caspase7 - 治療藥的開發
  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症
  • 開發中的產品:各企業
  • 開發中大學/機關
  • Caspase7 - 治療藥評估
  • 評估:各作用機制
  • 評估:各給藥途徑
  • 評估:各分子類型
  • Caspase7 - 開發治療藥的企業
  • Clayton Biotechnologies Inc
  • Derm-Biome Pharmaceuticals Inc
  • Histogen Inc
  • Takeda Pharmaceutical Co Ltd
  • Caspase7 - 藥物簡介
  • BaxB-01 - 藥物簡介
  • 產品概要
  • 作用機制 (MoA)
  • 研究開發 (R&D)的發展情形
  • DB-207 - 藥物簡介
  • emricasan - 藥物簡介
  • emricasan - 藥物簡介
  • Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - 藥物簡介
  • Caspase7 - 暫停中的產品
  • Caspase7 - 開發中止的產品
  • Caspase7 - 產品開發的里程碑
  • 關注的新聞和新聞稿
  • 附錄
  • 調查手法
  • 涵蓋範圍
  • 2次調查
  • 1次調查
  • 專家隊的檢驗
  • 聯絡處
  • 免責聲明
目錄
Product Code: GMDHC2850TDB

Summary:

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Caspase-7 (CASP7) is a human protein encoded by the CASP7 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves and activates sterol regulatory element binding proteins.

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders and Ophthalmology which include indications Age Related Macular Degeneration, Atopic Dermatitis (Atopic Eczema), Coronavirus Disease 2019 (COVID-19), Diabetic Retinopathy, Glomerulonephritis, Psoriasis, Solid Tumor and Zika Virus Infections.

The latest report Caspase 7 - Drugs In Development, 2021, outlays comprehensive information on the Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)
  • The report reviews Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Overview
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Companies Involved in Therapeutics Development
  • Clayton Biotechnologies Inc
  • Derm-Biome Pharmaceuticals Inc
  • Histogen Inc
  • Takeda Pharmaceutical Co Ltd
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Drug Profiles
  • BaxB-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DB-207 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • emricasan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Dormant Products
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Discontinued Products
  • Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Product Development Milestones
  • Featured News & Press Releases
  • May 19, 2021: Histogen and Amerimmune report publication on Emricasan in COVID-19
  • Mar 16, 2021: Histogen and Amerimmune announce first patient dosed in phase 1 study of Emricasan in symptomatic COVID-19 patients
  • Oct 06, 2020: Derm-Biome Pharmaceuticals reports positive results from a preclinical study in psoriasis
  • Jun 24, 2019: Conatus announces results from ENCORE-LF and ENCORE-PH phase 2b clinical trials in NASH Cirrhosis
  • Jun 24, 2019: Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis
  • Apr 30, 2019: Conatus Pharmaceuticals announces publication demonstrating that Emricasan Ameliorates Portal Hypertension, improves liver structure and function in a preclinical model of advanced cirrhosis
  • Apr 15, 2019: Conatus late-breaker oral presentation at EASL meeting details results of ENCORE-PH phase 2b clinical trial in patients with NASH cirrhosis and severe portal hypertension
  • Mar 21, 2019: Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis
  • Mar 13, 2019: Conatus Late-breaker oral presentation at EASL meeting to detail results of ENCORE-PH Phase 2b clinical trial in patients with NASH Cirrhosis and Severe Portal Hypertension
  • Feb 12, 2019: Conatus announces completion of enrollment in ENCORE-LF phase 2b clinical trial of Emricasan in patients with decompensated NASH cirrhosis
  • Jan 28, 2019: Conatus Pharmaceuticals announces publications expanding on previously reported results from completed phase 2 NAFLD-NASH, portal hypertension and liver cirrhosis clinical trials
  • Dec 05, 2018: Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
  • Oct 26, 2018: Derm-Biome Pharmaceuticals commences testing its proprietary compounds on skin microbiome targets.
  • Sep 20, 2018: Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
  • Jul 02, 2018: Conatus Pharmaceuticals' Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Clayton Biotechnologies Inc, 2021
  • Pipeline by Derm-Biome Pharmaceuticals Inc, 2021
  • Pipeline by Histogen Inc, 2021
  • Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021